active
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good morning Miss Scarlet, lovely day down here in Clayton county.... how's it going up in the ATL?
OT: SMTR pr:
Press Release Source: SmarTire Systems Inc.
SmarTire Confirms NHTSA Final Rule Requiring Tire Monitoring Systems
Monday April 11, 9:30 am ET
- Light vehicle tire monitoring legislation driving interest in other vehicle markets
RICHMOND, BC, April 11 /PRNewswire-FirstCall/ - SmarTire Systems Inc. (OTCBB: SMTR - News) reported today that the National Highway Traffic Safety Administration (NHTSA) has issued its final rule requiring all new passenger cars and light vehicles being manufactured for sale in the USA to be equipped with tire pressure monitoring systems (TPMS) by September 2007. The more stringent requirements of NHTSA's final rule can currently only be fulfilled by direct measurement systems such as the kind developed by SmarTire.
ADVERTISEMENT
"We are very pleased that the uncertainty surrounding TPMS legislation has been resolved and the rule is finally in place," says Robert Rudman, President and CEO of SmarTire. "SmarTire has invested considerable technical and financial resources in the development of direct measurement systems and the public deserves this higher standard of performance and reliability. This legislation has also driven interest in other vehicle markets such as trucks, buses, recreational vehicles and motorcycles and we anticipate this legislation will expand to cover these vehicles in the future. SmarTire's advanced direct measurement TPMS products have been chosen by some of the world's most prestigious manufacturers including Aston Martin in the automotive sector, New Flyer and MCI in the bus sector, and Monaco, Country Coach and Western RV in the recreational vehicle sector."
In November 2000, a U.S. federal transportation law was enacted to prevent the re-occurrence of automotive tragedies as experienced with Firestone equipped Ford sport utility vehicles. The Transportation, Recall, Enhancement, Accountability, and Documentation (TREAD) Act empowered NHTSA to improve vehicle safety through various initiatives including one regulation that requires the installation of low pressure warning systems in new vehicles to indicate when tires are significantly under-inflated.
About SmarTire Systems Inc.
SmarTire develops and markets proprietary advanced tire pressure monitoring and technology systems for the global automotive and transportation industries. The U.S. Government, through the TREAD Act, has legislated that all new passenger vehicles must be equipped with tire monitoring systems beginning with a phased implementation in 2006. SmarTire is capitalizing on the rapidly emerging OEM and aftermarket opportunities. The company's vision is to become the preeminent provider of wireless sensing and control systems for vehicles worldwide. Incorporated in 1987, SmarTire has offices in North America and Europe.
A comprehensive investment profile regarding SmarTire Systems Inc. may be found online at www.hawkassociates.com/smartire/profile.htm.
Additional information about SmarTire Systems can be found on the website www.smartire.com. An online investor kit containing SmarTire press releases, SEC filings, current price Level II quotes, interactive Java, stock charts and other useful information for investors can be found at www.hawkassociates.com and www.hawkmicrocaps.com. Investors may contact Randy Halischuk, or Judy Leclercq, SmarTire at (800) 982-2001 email: investor_relations@smartire.com or Frank Hawkins or Julie Marshall, Hawk Associates at (305) 852-2383, email: info@hawkassociates.com.
This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 which represent the company's expectations or beliefs concerning future events of the company's financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company's dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company's products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.
------------------------------------------------------------------------
Source: SmarTire Systems Inc.
My father would have killed to be in the Co of any of the players you mentioned and probably you too.
I love this part Medical history is unfolding right before our eyes and we own a part of it. DNAP will be a strong drug developer and share in your vision..... GOOOOOOOOOOOO DNAP!
INHO- I believe ann441h0, you have to hold or close above $5.00 a share for 90 consecutive days.
stockboy, I can't believe it! I guess there's a first time for everything.
Thank you
Thank you
Thank you
OT: Thanks, I think I know what you mean but this news Thursday should be good, correct?
OT: ebo783, do you think it's a good time to buy into AVN?
TONY IS DA-MAN....... I THINK I'M GOING TO CALL THIS....
THE YEAR OF HOPE
Great find vision2b, I noticed it took 5 years to get that patent.... looks like we may have 2 more for Tony with DNAP this year!!!
Brothers In Arms, you said,
I would really like for you to give me your input on what I had to say, good or bad, your input counts the most.
I wish you would post more.
OT: Hoping for a good week ahead for my other penny stock:
http://www.smartire.com/pdf/publishedarticles/April_2005_NA.jpg
I had to go back and find it to make sure:
There comes a time when you define the moment, or the moment defines you. - Tin Cup
The moment seems to have taken over easymedicine....
W2p, what's that line easymedicine use to have at the end... the moment defines you>>>>> I guess the moment defined him
stockboy, you said,
Does anyone have any idea how long to market this product let's say 2-5 years or what? A time frame would be nice.
IMHO- I have 3-4 years.
That's alright ann441j0!!!
ann441j0, you said,
I think I beat you to it! - lol
I say you bought your way in ... great buy!
Beginning of the week bashers everywhere prophetizing GLOOM & DOOM..... now no where to be found!!!
What a difference a good PR makes!!!
What a week.. first I was in hell>>>>>now I'm in heaven!!!
GOOOOOOOOOOOOOOOOOOOO DNAP!
TOOOOOOOOOOOOOOOOODAMOOOOOOOOOOOOOOOOOON!!!
That's something to really be thankful for.
Israel is a name that doesn't show up on any charts but it carries a lotta weight with a lotta people..... when that name shows up there's a movement that goes in concert.... call it a litte cultural tid-bit>>>>IMHO
That's funny...
Great news- thank you.... got this 20 min delay here!
After all the insults...... man you just gotta laugh BHAhAHAhhahahahahaha!! Darn that felt gooooooooooood.
Thank you lord!
Maybe something there Ann the next time you get ready to buy let me know.... so I can get in.
You must have bought a very large block indeed!!!
GOOOOOOOOOOOOOO ANN
GOOOOOOOOOOOOO DNAP!
Good afternoon Miss Scarlett.
easymedicine when will you do a chart on SMTR?.... I certainly would like to know what your charts say>>>> I don't have a clue about charts!
retired investor, BHAHAHAHAHA I tried to tell TD over on RB the same thing.... nobody is listening to you bashers.
OT: SMTR will hopefully start sign more contracts now that the government...
http://www.nhtsa.dot.gov/portal/site/nhtsa/template.MAXIMIZE/menuitem.f2217bee37fb302f6d7c121046108a...
NHTSA 08-05
Thursday, April 7, 2005 Contact: Rae Tyson,
Telephone: (202) 366-9550
NHTSA Releases Final Tire Pressure Monitoring Rule
All passenger cars will have tire pressure monitoring systems beginning with the 2006 model year according to a new motor vehicle safety standard by the National Highway Traffic Safety Administration (NHTSA.)
The regulation will require that manufacturers install a system that can detect when one or more of the vehicle’s tires are 25 percent or more below the recommended inflation pressure.
Phase-in of the new regulation will begin Sept. 1, 2005. All new 4-wheeled vehicles weighing 10,000 pounds or less must be equipped with the monitoring system by the 2008 model year.
According to NHTSA, under-inflated tires can adversely affect fuel economy, lead to skidding and loss of control and hydroplaning on wet surfaces. It can also increase stopping distance and the likelihood of tire failures.
NHTSA estimates that about 120 lives a year will be saved when all new vehicles are equipped with the tire pressure monitoring systems. In addition, consumers should see improved fuel economy and increased tire life. The manufacturers’ average cost per vehicle is estimated to be between $48.44 and $69.89, depending on the technology used.
The tire pressure monitoring system was required by Congress when it enacted the Transportation Recall Enhancement, Accountability, and Documentation (TREAD) Act in 2000. The new regulation can be found at: http://www.nhtsa.dot.gov/cars/rules/rulings/TPMSfinalrule.6/TPMSfinalrule.6.html.
The penny stock land is for dreamers and people that have a lotta hope. You don't invest down here expecting S & P 500 fundamentals.... well those of us who are realist don't. It is sad so many bashers just don;t get it. Ger real!
You guys should take a look at my other penny stock SMTR. The FDA are taking strides to help DNAP but the government is about to slam auto dealers with mandatory Tire Pressure Monitoring Systems... check out this news release:
US to Order Tire Pressure Monitors on New Vehicles
Wed Apr 6, 2005 05:33 PM ET
By John Crawley
WASHINGTON (Reuters) - U.S. regulators are set to make automakers equip all lightweight passenger vehicles with tire pressure monitors, concluding a fight over what technology to adopt that would keep costs down.
The regulation, due as early as Thursday, covers all cars and light trucks, including vans and sport utility vehicles. It is central to congressionally ordered safety changes stemming from the Firestone tire debacle several years ago.
Accidents caused by blowouts and tread separations killed nearly 300 people in the United States. Most of the rollover crashes involved Ford Explorer sport utilities. Firestone is a unit of Japan's Bridgestone Corp.
After legal and other delays, the National Highway Traffic Safety Administration will require auto companies to install sensors that measure pressure simultaneously on all four tires.
Industry sources say the requirement is mainly consistent with an agency proposal last September and a court ruling that rejected the government's first plan and ordered it to draft a tougher monitoring standard.
A spokeswoman for the auto safety agency would not comment on the regulation, which was in the works for years and will set a broad threshold for inflation pressure.
If tires are under-inflated by more than 25 percent, a dashboard light will warn motorists. But tire makers and some safety groups oppose a single alert level because tires vary in size and thickness.
A 25 percent drop in recommended pressure may leave some tires so under-inflated that they cannot safely carry a fully loaded vehicle, manufacturers say.
Under-inflation can expose rubber and other materials to more heat -- especially during hot weather -- and create dangerous wear at the edges and sides of a tire.
The government estimates the plan will cost industry between $800 million and $1.1 billion to phase in the technology on all new vehicles from this year through 2007.
Auto manufacturers do not oppose the requirement, which will apply to new vehicles. Properly inflated tires can help create a smoother ride, improve fuel efficiency, and reduce expensive tire maintenance and replacements.
Tire monitoring systems are already installed on between 2 million and 4 million vehicles, mainly luxury vehicles. Most pressure monitoring systems use sensors that are tied into anti-lock brakes.
In 2002, NHTSA proposed giving automakers the option of a direct monitoring system, which safety groups favor, and one that works with brakes, which is cheaper. But safety advocates successfully sued in federal court to force regulators to adopt the more stringent standard with a 25 percent pressure differential.
Nearly 20 percent of all towing calls received by AAA last year were tire related.
Amen ann441j.... I don't see it easy!
When I see the potential as you see in a good Co or kid...
BTW-great answer!
Some people look at a kid and see a president..... some people look at a kid and see a jail-bird.... which are you?
No I didn't buy anymore yet... don't have the money at present.
Leaders know who they are... evidently you don't know what's being said here. I guess you are just a spreader of FUD.
Yes they are fair questions and only individuals themselves can answer. I know this, leaders don't follow the pack they get out in front... step on up the pack will follow.
Good afternoon Miss Scarlet.... let me guess---- TEA?
Notable quote by management from recent PR:
"With the first pharmaceutical in our nascent drug pipeline, our Company is evolving into a genomics-based pharmaceutical company that develops innovative 'theranostic' products, which blend genomics-based tests with drugs as products to target segments of the patient population for enhanced efficacy and reduced side effects," stated DNAPrint genomics Chief Executive Officer Richard Gabriel. "Everything we have done as a company up until this point -- aggressively introducing new tests, forging new markets, expanding the envelope of genomics expectations in the fields of forensics, consumer genomics and pharmacogenomics -- has made today's announcement possible."
"DNAPrint genomics has taken a major step forward in establishing a drug pipeline that has the potential to provide the Company a significant opportunity for growth," stated Tony Frudakis, Ph.D., Founder and Chief Scientific Officer. "We are pleased that a prestigious organization such as Beth Israel Deaconess is embracing our innovative technology in the development of our first drug candidate."
http://biz.yahoo.com/prnews/050405/fltu002.html?.v=5
How do other credible sources view this event?....
Notable quote from Bio-itworld:
Bio-IT Briefs
By Bio-IT World Staff
Bio-IT World
In a step toward transforming itself into a genomics-based pharmaceutical company, DNAPrint Genomics Inc. today announced that it has acquired an exclusive worldwide license from Harvard Medical School's Beth Israel Deaconess Medical Center (BIDMC) to develop a new, more potent and longer-acting form of the anemia drug Erythropoietin (EPO). The royalty-bearing agreement creates an opportunity for DNAPrint Genomics to develop and market an improved "super"- EPO. EPO is currently commercialized by several pharmaceutical companies for a worldwide market that exceeds $10 billion. Website: www.dnaprint.com.
http://www.bio-itworld.com/news/040505_report8016.html
The world is just starting to find out what we already know.... the share price will follow!!!
I'm not worried about share price now because it will follow good management & science.
Management & Science from credible sources:
from recently filed 10k:
We continue to develop our relationship with the Moffitt Cancer Center in Tampa, Florida and have expanded our co-development of technologies using our proprietary technologies to study the relationship with medication treatment of cancer cells and genetic inheritance of specific genes that may affect a person's ability to respond to medications such as Taxol or Taxotere and other such medications used to treat cancer. We have seen several companies, including Celera and Genaissance; make public statements regarding the use of medicines and relationship to inherited markers. We will continue to explore, develop and test new approaches to problems that heretofore have been classified as the result of a drug treatment program gone awry. We believe generally that under each drug interaction can be found a series of genetic markers that may be linked to inherited markers, markers that we can track and identify, and prior to drug treatment, providing the patient, the doctor and the health care institution tangible savings in capital and patient aggravation.
We have completed our initial phase of research and development on a test to determine genetic predisposition for response to the Taxol-Carboplatin drug combination. The Taxol-Carboplatin drug combination therapy is a treatment for breast, ovarian, prostate and other cancers. In FDA clinical trials the Taxol-Carboplatin drug combination therapy demonstrated efficacy in only 60-70% of patients. In preliminary trials, our therapeutic response tests were 95% effective in distinguishing Taxol-Carboplatin responders from non-responders.
Enhanced Drug Marketing- By using our products and services, pharmaceutical companies may enhance the effectiveness of their marketing campaign resulting in improved profitability. The overlap of demographic segments and genetic predispositions offers a compelling opportunity for focused drug marketing. Armed with studies that indicate a drug is most effective within certain demographic segments, pharmaceutical companies can more effectively engage in target marketing. Although we do believe that pharmaceutical companies may enhance the effectiveness of their marketing campaign by using our products and services, as of December 31, 2004, no pharmaceutical companies have used our products or services with respect to demographic segments, genetic predispositions and drug marketing and achieved such results.
Expanded Drug Patent Life - There is also potential that packaging a drug with a genomic diagnostic test may extend the drug's patent life. Pharmaceutical companies that are struggling to find replacements for their aging drugs could benefit from a patent extension. Although we do believe that pharmaceutical companies can prepare a genomic diagnostic test and extend a drug's patent life, as of December 31, 2004, no pharmaceutical companies have used our products or services for such purpose or achieved such results. Our current technologies and services could be utilized by a pharmaceutical company to identify and develop a genomic diagnostic test. Alternatively, we could work with generic drug manufacturers and assist them in developing a genetic diagnostic test for off patent drugs. Our greatest, and possibly the most immediate, market potential is to create a testing service for physicians and patients that will allow them to determine if a particular medicine is right for the disease that has been diagnosed.
Increased Drug Development Success Rates - By incorporating genomic variation, clinical trials can be designed to include those patients most likely to benefit from the proposed therapeutic product. The use of a genomics strategy has the potential to yield improved response rates. While the number of clinical trial participants may not be reduced, drug trial efficacy would be greatly enhanced.
Rescue Failed Drugs - A pharmaceutical company may choose to initiate new clinical trials on drug candidates that previously failed. The failure of the earlier trial could have been because the earlier trial was conducted on a broad patient population. We could design a genetic test to predict patient response which would allow a smaller, more clearly defined group of patients to be identified for the new clinical trial; thereby enhancing the drug's efficacy and compliance and improving the likelihood of approval within a targeted group. Although we do believe that pharmaceutical companies can utilize our genetic test to predict patient response, as of December 31, 2004, no pharmaceutical companies have used our products or services for such purpose or achieved such results. Approval may require a physician to use the test to determine if a patient would be within the response group prior to prescribing the drug. We believe that this strategy will lead to more drug approvals and longer product life cycles, improving the return on capital for the pharmaceutical company and increasing the use of our tests.
Were they acting in harmony with their words?.....
Recent PR: http://biz.yahoo.com/prnews/050405/fltu002.html?.v=5
Notable quote from article:
"Our EPO technology has significant promise as a more powerful and commercially successful application of Erythropoietin," stated BIDMC's Dr. Arthur J. Sytkowski, who holds patents related to the new "Super"-EPO. "We are pleased that DNAPrint has made a commitment to work with BIDMC in expanding the potential for this drug."
The share price will follow!!!